Chargement en cours...
Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains treatment refractory. Immunotherapy has achieved success in the treatment of multiple malignancies. However, the efficacy of immunotherapy in PDAC is limited by a lack of promising biomarkers. In this research, we aimed to identify robust i...
Enregistré dans:
| Publié dans: | Front Immunol |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8320597/ https://ncbi.nlm.nih.gov/pubmed/34335594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.690056 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|